For the first time in years, a disease that can kill within hours is back in the headlines, and this time the government is moving fast to act.
Around one million young people across England are set to be offered the meningitis B vaccine following an unprecedented outbreak in Kent that alarmed public health officials throughout 2024. The one-off catch-up programme is a direct response to a cluster of cases that was larger and more sustained than anything seen in recent memory.
Meningitis B is caused by the Neisseria meningitidis group B bacteria and remains one of the most dangerous infectious diseases in the UK. It can progress from the first symptoms to life-threatening illness in under 24 hours, which is precisely why speed of vaccination matters so much.
The MenB vaccine, known as Bexsero, is already routinely offered to babies on the NHS schedule at two, four, and twelve months old. The problem is that a significant chunk of older teenagers and young adults missed out entirely, either because they were born before the programme launched in 2015 or because they aged out of eligibility before it expanded.
Those aged 15 to 25 are considered the priority group for this new offer, as they carry the highest rates of the bacteria asymptomatically while also being most vulnerable to serious infection. University students living in halls, in particular, have long been flagged as a higher-risk cohort.
Public health specialists have welcomed the announcement, with one NHS consultant describing the Kent outbreak as “a wake-up call that we couldn’t ignore.” The scale of what happened in Kent made it impossible to treat this as a localised issue any longer.
“We’ve known for a while that there was a gap in coverage for this age group. This programme finally starts to close it.”
Parents of teenagers who missed the baby programme are being urged not to wait for a formal letter before contacting their GP. Eligibility details are expected to be confirmed in the coming weeks.
The bigger question now is whether a short-term catch-up is enough, or whether this signals a permanent shift in how the NHS approaches meningitis B coverage for adolescents going forward.
